Barclays PLC Increases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Barclays PLC lifted its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 141.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 116,024 shares of the biotechnology company’s stock after purchasing an additional 67,948 shares during the period. Barclays PLC’s holdings in REGENXBIO were worth $1,217,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. National Bank of Canada FI acquired a new position in shares of REGENXBIO during the 3rd quarter worth about $713,000. Stifel Financial Corp grew its holdings in shares of REGENXBIO by 13.3% during the third quarter. Stifel Financial Corp now owns 149,280 shares of the biotechnology company’s stock worth $1,566,000 after purchasing an additional 17,563 shares during the last quarter. Redmile Group LLC boosted its position in shares of REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after purchasing an additional 323,100 shares during the period. Erste Asset Management GmbH acquired a new stake in shares of REGENXBIO in the 3rd quarter valued at about $140,000. Finally, Verition Fund Management LLC purchased a new position in REGENXBIO during the 3rd quarter worth approximately $432,000. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at REGENXBIO

In related news, Director Argeris N. Karabelas sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. This represents a 46.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.13% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on RGNX shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 target price on shares of REGENXBIO in a report on Friday, November 15th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $35.00 price objective on shares of REGENXBIO in a report on Wednesday, December 11th. HC Wainwright reduced their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Chardan Capital reaffirmed a “buy” rating and set a $52.00 price target on shares of REGENXBIO in a research note on Wednesday, November 20th. Finally, StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Two research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Stock Down 5.8 %

Shares of REGENXBIO stock opened at $7.41 on Monday. The business’s fifty day moving average is $9.27 and its two-hundred day moving average is $10.94. REGENXBIO Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $28.80. The firm has a market cap of $367.13 million, a PE ratio of -1.47 and a beta of 1.24.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.